Immunovant Inc.
(IMVT)
undefined
undefined%
At close: undefined
26.28
-0.17%
After-hours Dec 13, 2024, 05:19 PM EST
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
The company was incorporated in 2018 is headquartered in New York, New York.
Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant Inc.
| Country | United States |
| IPO Date | Jun 21, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 207 |
| CEO | Dr. Peter Salzmann M.B.A., M.D. |
Contact Details
Address: 320 West 37th Street New York, New York United States | |
| Website | https://immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Salzmann M.B.A., M.D. | Chief Executive Officer & Director |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Eva Renee Barnett M.B.A. | Chief Financial Officer |
| Mark S. Levine J.D. | Chief Legal Officer & Corporate Secretary |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Andy Deig | Senior Vice President of Strategic Finance |
| Christine Blodgett | Senior Vice President of Human Resources |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer |
| Lauren Schrier M.B.A. | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 3 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |